Trichome

Therapeutic inertia (also known as clinical inertia[1]) is a measurement of the resistance to therapeutic treatment for an existing medical condition. It is commonly measured as a percentage of the number of encounters in which a patient with a condition received new or increased therapeutic treatment out of the total number of visits to a health care professional by the patient. A high percentage indicates that the health care provider is slow to treat a medical condition. A low percentage indicates that a provider is extremely quick in prescribing new treatment at the onset of any medical condition.

Calculation[edit]

There are two common methods used in calculating therapeutic inertia. For the following examples, consider that a patient has five visits with a health provider. In four of those visits, a condition is not controlled (such as high blood pressure or high cholesterol). In two of those visits, the provider made a change to the patient's treatment for the condition.

In Dr. Okonofua's original paper, this patient's therapeutic inertia is calculated as where h is the number of visits with an uncontrolled condition, c is the number of visits in which a change was made, and v is the total number of visits.[2] Therefore, the patient's therapeutic inertia is .

An alternative, which avoids consideration of visits where the condition was already controlled and the provider should not be expected to make a treatment change, is . Using the above example, there are 2 changes and 4 visits with an uncontrolled condition. The therapeutic inertia is .

Reception[edit]

Therapeutic inertia was devised as a metric for measuring treatment of hypertension. It has now become a standard metric for analysing treatment of many common comorbidities such as diabetes[3] and hyperlipidemia.[4] Both feedback reporting processes and intervention studies aimed at reducing therapeutic inertia have been shown to increase control of hypertension,[5] diabetes, and hyperlipidemia.

References[edit]

External links[edit]

  • OQUIN: The OQUIN:Hypertension Initiative at MUSC performed the initial study and reporting on therapeutic inertia.

Leave a Reply